Oct. 17 (Bloomberg) -- Pharmaxis Ltd. shares were placed in a trading halt in Australia. The European Committee for Medicinal Products for Human Use is due to form an opinion on the reexamination of Bronchitol for the treatment of cystic fibrosis during its meeting in London this week and the company’s doesn’t expect to receive definitive notification until Oct. 21, Pharmaxis said in a regulatory filing.

Link to Statement:{NSN LT75HT3PR6RK <GO>}

To contact the editor responsible for this story: Victoria Batchelor at vbatchelor@bloomberg.net